Thermo Fisher Scientific (TMO) Q2 2026: Revenue +10.5%, Organic Growth 5%, Cash -58% on Clario Deal
Unit note: Thermo Fisher Scientific is a U.S.-listed company (NYSE: TMO) and reports in U.S. dollars. This analysis uses millions of dollars (M$) as the base unit.
Thermo Fisher Scientific posted Q2 FY2026 (April–June 2026) revenue of $11,994 million, up 10.5% year over year. That headline number should not be read directly as a demand recovery, however. The company's own 10-Q decomposition shows that reported 10% revenue growth = acquisitions +5 percentage points + currency +1 percentage point + organic growth 5%, while on a first-half basis the breakdown is reported 8% = acquisitions +4pp + currency +2pp + organic 3%. Roughly half of top-line expansion came from Clario, acquired at the end of March.
Operating income rose to $2,087 million, +13.8%; net income attributable to common shareholders reached $1,736 million, +7.4%; and GAAP diluted EPS was $4.68 (vs. $4.28 a year earlier, +9.3%). The widely tracked non-GAAP adjusted EPS was $6.03, up 12.5% from $5.36 (H1: $11.47, +9%). The company raised its full-year guidance alongside the results, targeting revenue of $47.4–$48.1 billion (reported basis, +6–8%), organic growth of approximately 4% (vs. prior 3–4%), and adjusted EPS of $24.93–$25.33.
Meanwhile, $8,872 million in corporate acquisitions (investing cash outflows) combined with $4,000 million in share repurchases cut the cash balance from $9,852 million to $4,064 million — a 58.7% decline — and net debt expanded from approximately $29.3 billion to $38.2 billion.
- Consolidated Balance Sheet Analysis
1-1. Key Asset Comparison (December 31, 2025 → June 27, 2026)
| Item | Prior Period (M$) | Current Period (M$) | Change | Interpretation |
|------|----------|----------|--------|------|
| Cash and cash equivalents | 9,852 | 4,064 | -58.7% | Depleted by large M&A and $4,000M share repurchases |
| Trade receivables, net | 8,900 | 9,451 | +6.2% | Increase trails H1 revenue growth of +8.4% — no collection red flags |
| Inventories | 5,425 | 5,627 | +3.7% | Raw materials +6.1%, WIP +7.1%, finished goods +0.9% |
| Property, plant and equipment, net | 10,565 | 10,755 | +1.8% | H1 capex of $826M reflected, offset by depreciation |
| Acquired intangible assets, net | 15,838 | 18,606 | +17.5% | Net increase of $2,768M from new M&A |
| Goodwill | 49,362 | 54,832 | +11.1% | $5,470M in acquisition premium added |
| Total assets | 110,343 | 113,174 | +2.6% | |
Two changes stand out. First, the $5,788M cash decline reflects M&A (net cash outflow of $8,872M) and share repurchases ($4,000M) outpacing H1 operating cash flow ($3,317M) plus net new borrowings ($3,826M). The $10 billion cash buffer that had served as a financial cushion is now less than half that level. Second, the combined $8,240M net increase in goodwill and intangibles fundamentally changes the character of the balance sheet — approximately 65% of total assets are now intangible (goodwill 48.4% + acquired intangibles 16.4%), raising impairment risk should any business unit underperform. The trade-receivables increase (+6.2% vs. year-end) trails H1 revenue growth (+8.4%), indicating no collection deterioration.
1-2. Liability Structure — Financial Debt vs. Operating Liabilities
Financial debt (carrying value) stood at $42,284 million, up 7.9% (+$3,110M) from $39,172 million at year-end. During the quarter, the company issued $5,238 million in new bonds — including a 10-year note due 2036 (4.902%, $1,300M), a 20-year note due 2046 (5.546%, $750M), and a 5-year note due 2031 (4.215%, $1,000M) — and repaid $1,412 million. Five Swiss franc-denominated bonds (maturities: 2036/2038/2041/2046/2056, aggregate $1,432M) were also issued in March 2026. A $5,000 million multicurrency revolving credit facility (expires January 7, 2028, currently undrawn) provides a liquidity backstop. Many existing euro- and yen-denominated bonds carry coupons of 0.77%–2%, while new dollar bonds issued this quarter carry 4.2%–5.5%. As low-coupon legacy bonds mature and are refinanced at current rates, interest expense will ratchet up in a stepwise fashion — Q2 interest expense was already $401 million.
Operating liabilities showed mixed trends vs. year-end: accounts payable $3,268M (-9.8%), accrued compensation $1,694M (-15.1%), deferred revenue $2,918M (+7.7%), other accrued liabilities $3,823M (+14.9%). The increases in deferred revenue and other accrued liabilities include balances acquired with Clario (preliminary purchase price allocation: deferred revenue $375M), limiting the usefulness of those comparisons as standalone operating signals.
1-3. Equity Structure
Paid-in capital (par value + additional paid-in capital): $446M + $18,870M = $19,316M
Retained earnings: $62,194M (vs. $59,156M at year-end, +5.1%)
Treasury stock: ($26,370M) (vs. ($22,309M), expanded by $4,061M)
Total stockholders' equity attributable to Thermo Fisher: $52,679M (vs. $53,407M, -1.4%)
Retained earnings grew by $3,038M — net income attributable to shareholders of $3,387M minus dividends declared of $349M — but $4,000M of share repurchases more than offset the gain, leaving equity marginally lower. The company returned approximately 128% of earnings (repurchases $4,000M + dividends paid $337M) during the half year, with the excess funded by borrowings. Total debt as a percentage of stockholders' equity rose to approximately 80% (422/526) from 73% at year-end, a meaningful step-up in financial leverage.
- Consolidated Income Statement Analysis
2-1. Key Revenue Metrics
Q2 2026 vs. Q2 2025 (three months)
| Item | Prior Period (M$) | Current Period (M$) | Change |
|------|----------|----------|--------|
| Revenue | 10,855 | 11,994 | +10.5% |
| — Product revenue | 6,249 | 6,823 | +9.2% |
| — Service revenue | 4,605 | 5,171 | +12.3% |
| Operating income | 1,834 | 2,087 | +13.8% |
| Operating margin (%) | 16.9% | 17.4% | +0.5pp |
| Net income attributable to Thermo Fisher | 1,617 | 1,736 | +7.4% |
| Net margin (%) | 14.9% | 14.5% | -0.4pp |
| GAAP diluted EPS ($) | 4.28 | 4.68 | +9.3% |
| Adjusted EPS ($, non-GAAP) | 5.36 | 6.03 | +12.5% |
Revenue growth decomposition (per company disclosure)
| Component | Q2 2026 | H1 2026 |
|------|---------|---------|
| Reported revenue growth | 10% | 8% |
| — Acquisitions | +5pp | +4pp |
| — Currency | +1pp | +2pp |
| Organic growth (non-GAAP) | 5% | 3% |
H1 2026 vs. H1 2025 (six months): Revenue $22,999M (+8.4%), operating income $3,950M (+11.2%), net income attributable to Thermo Fisher $3,387M (+8.4%).
By segment, Life Sciences Solutions +12.6% and Laboratory Products and Biopharma Services +11.6% (Clinical Research +22.6%) led growth. Those are reported figures, not organic — a significant portion of the LPBS and Clinical Research increase reflects Clario, consolidated from March 24, and the LSS gain includes the filtration and separation business acquired from Solventum in September 2025. Geographically, Europe +17.0%, Asia-Pacific +9.6%, North America +7.5% — but the European figure absorbs a disproportionate share of the company-wide +1pp currency tailwind, making it an imperfect proxy for underlying local demand. Management noted demand improvement across pharma/biotech, industrial/applied, and diagnostics/healthcare end markets in Q2; academic and government was roughly flat for the first half.
The 0.5pp operating margin improvement reflects a near-flat gross margin (40.6%→40.7%) — product GPM improved to 49.3% from 48.2%, but service GPM fell to 29.4% from 30.4%, largely offsetting — with the net gain driven primarily by SG&A growing below revenue (+9.0% vs. revenue +10.5%) and stable R&D (+3.4%). Net margin contracted because (1) interest income fell sharply ($297M→$207M, -30.3%) as cash was deployed, and (2) the effective tax rate ticked up (Q2: 6.5% vs. 5.6% in the prior-year quarter).
2-2. Fixed vs. Variable Cost Analysis
Q2 cost structure, reclassified:
Variable (cost of product and service revenues): $3,462M + $3,650M = $7,112M (59.3% of revenue, vs. 59.4%)
Fixed (SG&A + R&D + restructuring): $2,333M + $364M + $98M = $2,795M (23.3% of revenue, vs. 23.7%) — fixed-cost ratio down 0.4pp
When revenue grew 10.5%, SG&A grew only 9.0% and R&D only 3.4%, demonstrating operating leverage. Note that roughly half of revenue growth came from acquired businesses, so the leverage reflects both volume effects and the cost structure of the consolidated entities. The margin improvement was achieved despite $98M of restructuring charges in Q2 ($147M in H1). During the first half, the company reduced headcount by approximately 1% of total employees and consolidated facilities. As of July 31, it plans to record an additional approximately $220 million of restructuring charges, primarily in LPBS, mainly during 2026, with further actions under evaluation.
- Cash Flow Statement Analysis (H1, six months)
| Item | Prior Period (M$) | Current Period (M$) | Change |
|------|----------|----------|------|
| Cash from operating activities | 2,122 | 3,317 | +56.3% |
| Cash from investing activities | (815) | (8,797) | -7,982 |
| Cash from financing activities | (1,093) | (478) | +615 |
| Period-end cash and restricted cash | 4,603 | 4,096 | -507 |
The $1,195M surge in operating cash flow far exceeded net income growth (+$267M), driven by improved working capital consumption (from -$2,151M to -$1,537M, a $614M improvement) and higher depreciation and amortization (+$106M). Combined D&A of $1,553M ($638M depreciation + $915M intangible amortization) represents approximately 46% of H1 net income ($3,397M), confirming solid earnings-to-cash conversion.
Investing cash outflow of $8,797M is almost entirely attributable to corporate acquisitions ($8,872M net of cash acquired). That figure aggregates Clario with two proteomics software companies (U.S. and Germany) acquired in the Analytical Instruments segment. The preliminary Clario purchase price allocation recorded $5,934M of goodwill, $3,796M of acquired intangibles, $375M of deferred revenue, and $645M of deferred tax liabilities (balance-sheet movements differ from these preliminary amounts due to pre-existing amortization and currency). The weighted-average amortization life of acquired intangibles is 15 years, implying approximately $253M of annual amortization ($63M per quarter). Capital expenditures of $826M (vs. $656M a year earlier, +25.9%) expanded in parallel.
Financing cash outflow of $478M nets $5,238M of bond issuances, $1,412M of debt repayments, $4,000M of share repurchases, and $337M of dividends. The company effectively issued bonds to fund both the acquisition and the buyback.
Free cash flow (FCF) = $3,317M − $826M = $2,491M (vs. $1,466M a year earlier, +70%). FCF margin was 10.8%. In the half, the company returned 160% of FCF via buybacks ($4,000M) and 14% via dividends ($337M) — the shortfall relative to FCF was debt-funded.
- Five Key Findings
① $9,098 million Clario Holdings acquisition. On March 24, 2026, the company acquired Clario Holdings — a clinical-trial endpoint data solutions company — into the Laboratory Products and Biopharma Services segment. Total consideration of $9,098M comprised cash paid $5,806M + assumed debt repaid $3,180M + deferred consideration $121M + contingent consideration fair value $108M − cash acquired $117M. Goodwill of $5,934M was recorded and is not tax-deductible. This is the largest transaction since the PPD acquisition (completed December 2021). Acquired intangibles of $3,796M (customer relationships $2,510M, product technology $844M, order backlog $423M, trade names $19M) carry a weighted-average amortization life of 15 years, implying approximately $253M of annual amortization ($63M per quarter). Since the acquisition closed at the end of March, this burden is already reflected in Q2 results; H2 will capture a full two quarters. All purchase price allocations are preliminary and subject to adjustment, principally for intangibles, deferred revenue, and deferred taxes.
② Remaining performance obligations (RPO) of $29.7 billion — roughly 2.5 quarters of revenue. Of that, 52% is expected to be recognized within 12 months, covering approximately one-third of the next year's estimated revenue. The remaining 48% is embedded in contract manufacturing, clinical research, and extended warranty contracts (typically 3–5 year terms), providing durable long-term revenue visibility. Note that the RPO balance includes Clario-related amounts, limiting direct comparison to prior periods.
③ Effective tax rate of 6.5% — a recurring pattern, not a one-off. The H1 effective rate of 6.5% is well below the U.S. statutory rate of 21%. In 2026, discrete tax benefits totaled $323M ($175M from a Q1 domestication-related deferred tax benefit + $148M from deferred tax asset realization in Q2). However, the prior-year Q2 effective rate was an even lower 5.6%, and 2025 also included comparable discrete benefits ($125M in Q1 + $153M + $93M = $371M total). This is a pattern sustained for at least two consecutive years, not an isolated quarter. The company operates in more than 70 countries and benefits from tax incentives and lower effective rates relative to U.S. statutory levels. Rather than treating tax-rate normalization as an inevitable EPS headwind, the more appropriate discipline is verifying each quarter whether the pattern remains intact. Unrecognized tax benefits stand at $410M. Management stated that the One Big Beautiful Bill Act (OBBBA), effective July 4, 2025, has a "not material" impact.
④ Europe revenue +17.0%. European revenue of $3,311M vs. $2,830M contributed $481M of the $1,139M total revenue increase — 42% of the company-wide gain. This growth rate embeds both currency tailwinds and acquisition effects; organic local-market improvement is smaller. Continued euro strength would add further translation gains in H2; a reversal would be a symmetric headwind.
⑤ Hedge portfolio restructuring — euro net investment hedge fully unwound. The notional value of Swiss franc cross-currency swaps (net investment hedges) expanded from $5,000M to $11,800M, a 2.4× increase, while yen swaps were reduced from $4,650M to $1,100M and euro swaps were entirely eliminated (from $1,000M to zero). Currency forward notionals also declined to $1,496M from $2,248M. The company has effectively concentrated its net investment hedging into a single currency — the Swiss franc — leaving euro net assets largely unhedged. This means euro/dollar moves flow more directly into reported earnings, which is relevant context for finding ④. The net derivative liability position ($268M assets − $667M liabilities = −$399M) expanded, reflecting both this repositioning and U.S. dollar weakness.
- Key Takeaways and Outlook
The most accurate summary of Thermo Fisher's quarter is that the direction of recovery is correct, but the pace is slower than the headline numbers imply. Reported revenue growth north of 10% is the first of that magnitude since the pandemic winddown (2023: -4.6%, 2024: +0.05%, 2025: +3.9%), but organic growth was only 5% in Q2 and 3% for the first half. The modest upward revision to the full-year organic growth target — to approximately 4% from the prior 3–4% range — reflects the same reading. Double-digit growth in BioProduction and Clinical Research is encouraging, but at least two to three more quarters of acquisition-adjusted trend data are needed before declaring a full-cycle re-ignition.
Bull case: (1) 52% of $29.7B in RPO is scheduled for recognition within 12 months, providing near-term revenue visibility; (2) Clario synergies ramp from 2027; (3) Europe and Asia-Pacific growth continues; (4) further operating leverage drives margin expansion. Company guidance: full-year revenue $47.4–$48.1 billion, adjusted EPS $24.93–$25.33.
Risk factors: (1) Cash fell 58.7% to $4,064M, constraining capacity for additional M&A (2) total debt of $42,284M, with low-coupon legacy bonds rolling into high-rate refinancing — escalating interest expense; (3) intangibles represent approximately 65% of total assets — material impairment exposure if business units disappoint; (4) organic growth (Q2: 5%, H1: 3%) is roughly half the reported rate — when acquisition effects fade in 2027, a growth gap may emerge; (5) H1 share repurchases of $4,000M exceeded FCF of $2,491M — the sustainability of debt-funded shareholder returns warrants monitoring.
For investors tracking Korean markets, Thermo Fisher is simultaneously a global competitor to Samsung Biologics and Celltrion in CDMO and a supplier of biotech R&D infrastructure. Extrapolating this quarter's results directly to Korean CDMO order trends is a stretch, however — with half of growth coming from acquisitions, the most transferable signal is the company's qualitative assessment of "improving underlying conditions in the pharma and biotech end market." Service revenue growing faster than product revenue (+12.3% vs. +9.2%) also reflects Clario's consolidation rather than a broad instruments-and-consumables upturn, so mapping the trend to Korean life-science equipment and consumables companies requires caution. The structural growth in clinical research and data services is the more appropriate lens.
Disclaimer
This report is prepared for informational purposes based on the 10-Q quarterly report filed with the U.S. Securities and Exchange Commission (SEC) and does not constitute investment advice. Organic growth and adjusted EPS are non-GAAP measures as presented by the company.